Terry Becker, MD
Obstetrics · Kearney, NENPI 1447334214
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 232 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AbbVie at 25.2% of the total. Reporting peaked in 2019 at $1,129 and has fallen 83.2% since, to $189 in 2025.
Across 232 payments — averaging $14.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$843
- Amgen$360
- AstraZeneca$345
- Johnson & Johnson$253
- GSK$247
- Novo Nordisk$243
- plus $1K from 23 others
What the payments were for
- Food & beverage$3,341100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 57 | $843 |
| Amgen | 26 | $360 |
| AstraZeneca | 6 | $345 |
| Johnson & Johnson | 20 | $253 |
| GSK | 25 | $247 |
| Novo Nordisk | 18 | $243 |
| Novartis | 23 | $206 |
| Sanofi-aventis U.S. LLC | 12 | $160 |
| Astellas Pharma US Inc | 5 | $104 |
| Lilly USA, LLC | 7 | $98 |
| Boehringer Ingelheim | 6 | $75 |
| Otsuka America Pharmaceutical, Inc. | 3 | $68 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $42 |
| Avanir Pharmaceuticals, Inc. | 3 | $37 |
| Exact Sciences | 2 | $34 |
| Inspire Medical Systems, Inc. | 1 | $28 |
| Ultragenyx Pharmaceutical Inc. | 2 | $26 |
| Genentech USA, Inc. | 2 | $24 |
| Organon | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Biogen | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYMBICORT$298
- FARXIGA$298
- BYDUREON$193
- BREZTRI AEROSPHERE$105
How this compares
Too few obstetrics providers in Nebraskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 141 | $114,253 |
| JardianceEmpagliflozin | 97 | $90,934 |
| JanuviaSitagliptin Phosphate | 98 | $72,123 |
| EliquisApixaban | 86 | $61,033 |
| OzempicSemaglutide | 39 | $56,081 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $36,461 |
| TradjentaLinagliptin | 33 | $23,391 |
| MyrbetriqMirabegron | 43 | $20,412 |
| Tresiba Flextouch U-100Insulin Degludec | 34 | $19,505 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $19,496 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $13,452 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 17 | $11,415 |
| Praluent PenAlirocumab | 14 | $9,509 |
| Atorvastatin Calcium | 847 | $8,551 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $8,527 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat, Spiriva Respimat | $75 | $131,971159 claims |
| Johnson & JohnsonXarelto | $253 | $114,253141 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $247 | $58,44078 claims |
| Novo NordiskOzempic | $243 | $56,08139 claims |
| Astellas Pharma US IncMyrbetriq | $104 | $20,41243 claims |
| AstraZenecaSymbicort, Breztri Aerosphere, Bevespi Aerosphere | $345 | $19,63542 claims |
| NovartisEntresto | $206 | $7,23521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few obstetrics providers in Nebraskaon file to place this against a meaningful peer group, so we don't.
Other obstetrics in Kearney
- Bradley RodgersKearney$15K
- Beth ErnstKearney$4K
- Clinton JonesKearney$38
- Erica HaakeGrand Island$10K
- Donald GibbensLincoln$2K
- Dennis HodgeLincoln$498
- Meghen BokemperLincoln$376
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.